Cargando…

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

BACKGROUND: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamphuis, Esmé, Boesjes, Celeste M., Loman, Laura, Bakker, Daphne S., Poelhekken, Mila, Zuithoff, Nicolaas P. A., Kamsteeg, Marijke, Romeijn, Geertruida L. E., van Wijk, Femke, de Bruin‐Weller, Marjolein S., de Graaf, Marlies, Schuttelaar, Marie L. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107870/ https://www.ncbi.nlm.nih.gov/pubmed/36564878 http://dx.doi.org/10.1111/pai.13887

Ejemplares similares

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
por: Voorberg, Angelique N., et al.
Publicado: (2022)

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
por: Spekhorst, Lotte S., et al.
Publicado: (2020)

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
por: ARIËNS, Lieneke F. M., et al.
Publicado: (2021)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Dupilumab facial redness: Positive effect of itraconazole
por: de Beer, Fleur S.A., et al.
Publicado: (2019)

Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial
por: Voorberg, Angelique N., et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on adults with moderate-to-severe atopic dermatitis in the Dutch general population
por: Zhang, Junfen, et al.
Publicado: (2021)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab
por: Loman, Laura, et al.
Publicado: (2020)

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
por: Bakker, Daphne S., et al.
Publicado: (2021)

Patients' perspectives on quality of care for chronic hand eczema: A qualitative study
por: Sloot, Manon M., et al.
Publicado: (2022)

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
por: Bakker, D.S., et al.
Publicado: (2019)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
por: Bakker, Daphne S., et al.
Publicado: (2020)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Exposure and work‐related factors in subjects with hand eczema: Data from a cross‐sectional questionnaire within the Lifelines Cohort Study
por: Brands, Marjolein J., et al.
Publicado: (2022)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Posttraumatic unilateral perniosis: A case report
por: Boesjes, Celeste Mirte, et al.
Publicado: (2019)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Immune monitoring and treatment in immune-mediated inflammatory diseases
por: van Wijk, Femke, et al.
Publicado: (2022)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Hand eczema and lifestyle factors in the Dutch general population: Evidence for smoking, chronic stress, and obesity
por: Loman, Laura, et al.
Publicado: (2021)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Smoking and obesity are associated with chronic hand eczema and severity of hand eczema: Data from the Dutch general population
por: Loman, L., et al.
Publicado: (2022)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Baricitinib treatment of severe chronic hand eczema: Two case reports
por: Rosenberg, Fieke M., et al.
Publicado: (2022)

Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study
por: VOORBERG, Angelique N., et al.
Publicado: (2022)

The positive impact of rituximab on the quality of life and mental health in patients with pemphigus
por: Rashid, Hanan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jrt1qvpbf4e6df504a5d69icb